Core Viewpoint - The Hong Kong innovation drug sector is experiencing a significant decline, with the Hong Kong Innovation Drug ETF (520880) hitting a nearly five-month low, prompting potential "bottom-fishing" activities from investors [1][3]. Group 1: Market Performance - The Hong Kong Innovation Drug ETF (520880) dropped by 2.77%, reaching a new low, with leading stocks like Kangfang Biotech down over 5% and BeiGene down more than 6% [1]. - Despite the downturn, there has been a strong buying interest, as evidenced by a net inflow of over 136 million yuan over five consecutive days of purchases [1]. Group 2: Industry Outlook - The sentiment in the innovation drug sector has shown volatility, but the long-term outlook remains positive, with expectations for increased global competitiveness and successful commercialization by Q1 2026 [3]. - The National Healthcare Security Administration emphasized the importance of integrating innovative drug listings into commercial health insurance, which is expected to bolster the sector [3]. Group 3: ETF Characteristics - The Hong Kong Innovation Drug ETF (520880) is the largest in its category, with a total scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan since its inception [4]. - The ETF's index, the Hang Seng Hong Kong Innovation Drug Select Index, has a significant concentration in leading companies, with the top ten stocks accounting for over 72% of the index weight [4].

Core Viewpoint - The Hong Kong innovation drug sector is experiencing a significant decline, with the Hong Kong Innovation Drug ETF (520880) hitting a five-month low, prompting potential "bottom-fishing" activities from investors [1][7]. Market Performance - The Hong Kong Innovation Drug ETF (520880) fell by 2.77%, marking a new low in five months, with leading stocks like CanSino Biologics dropping over 5% and BeiGene falling more than 6% [1][7]. - Despite the downturn, there has been a strong buying interest, as evidenced by a net inflow of over 136 million yuan in the past week, with five consecutive days of net purchases [1][7]. Industry Outlook - The sentiment in the innovation drug sector has shown volatility, but the long-term outlook remains positive, with expectations for increased global competitiveness and successful commercialization by Q1 2026 [3][9]. - The National Healthcare Security Administration emphasized the importance of implementing commercial insurance for innovative drugs, encouraging the inclusion of reasonable medical expenses outside the basic insurance catalog [3][9]. ETF Characteristics - The Hong Kong Innovation Drug ETF (520880) is the largest in its category, with a total size of 2.142 billion yuan and an average daily trading volume of 458 million yuan since its inception [5][10]. - The index tracked by the ETF, the Hang Seng Hong Kong Innovation Drug Select Index, has a significant concentration in leading companies, with the top ten stocks accounting for over 72% of the index weight [5][10]. Risk Management - The ETF employs a strategy to mitigate risks associated with less liquid stocks by enforcing a forced reduction in weight for these components, thereby controlling tail risks [4][9].

Group 1 - Hong Kong innovative drug concept stocks experienced a decline in early trading, with Kelun-Botai Biopharmaceuticals falling over 7%, BeiGene and 3SBio dropping over 5%, and CanSino Biologics and Hansoh Pharmaceutical decreasing over 4% [1] - The related ETFs for innovative drugs in Hong Kong also saw a decline of approximately 2% [1] Group 2 - Several brokerages noted that an increasing number of innovative drug companies are transitioning from the "R&D investment phase" to the "commercialization phase," with core product sales revenue steadily growing, and some companies achieving a transition from losses to profitability, providing solid support for stock prices [2] - Institutional investors, such as public funds, are increasing their allocation to high-quality targets, leading to a continuous rise in market recognition [2] - The focus of the innovative drug market has shifted from broad valuation recovery to the ability of companies to deliver on their fundamentals [2]

Summary of the Conference Call on the Pharmaceutical Industry Industry Overview - **Industry**: Pharmaceutical Industry - **Rating**: Leading - **2026 Outlook**: Value recovery, upward trend continues, selective layout amidst differentiation [1] Core Insights and Arguments - **Industry Trends**: - The industry is expected to maintain a relatively fast growth rate despite tightening drug regulations and increasing challenges in new drug development in the U.S. [2] - The integration trend within the industry is just beginning, with leading players in high-growth segments showing strong long-term certainty [2] - **Private Hospitals**: - High-quality private hospital targets are recommended as cost control pressures ease and outdated capacities are eliminated, allowing for a return to faster growth [3] - Recommended stocks include Gushengtang and Haijia Medical, which are expected to rebound in the short term and have clear long-term expansion paths [3] - **Valuation Summary**: - A detailed table of various pharmaceutical companies with their stock codes, ratings, target prices, closing prices, earnings per share (EPS), price-to-earnings ratios (P/E), and other financial metrics is provided [4] Important but Overlooked Content - **Market Performance**: - The MSCI China Pharmaceutical Index increased by 62.0% year-to-date, outperforming the MSCI China Index by 31.8 percentage points [10] - The pharmaceutical sector has officially entered a rebound phase, with significant performance differentiation among sub-sectors [10] - **Policy Environment**: - The policy environment is improving, with the government supporting innovative drug development and introducing commercial insurance funds to supplement the medical insurance directory [11] - The latest round of medical insurance negotiations has successfully included 127 drugs outside the directory, indicating a shift towards a more balanced pricing strategy [11] - **Innovation and R&D**: - The industry is witnessing a positive cycle of R&D breakthroughs and global licensing, with many companies entering a "R&D investment - clinical breakthrough - global licensing" cycle [11] - As of September 2025, Chinese pharmaceutical companies have completed 103 overseas transactions, exceeding 77% of the total transaction amount for 2024 [11] - **Financial Performance**: - The overall revenue of the A-share pharmaceutical sector showed a marginal recovery in Q3 2025, with a 0.7% year-on-year increase, indicating strong operational resilience [17] - The sector's earnings growth expectations are improving, with leading companies showing rapid recovery in performance [11][20] - **Investment Opportunities**: - The report emphasizes two main investment lines: focusing on innovative companies with strong differentiation and product export potential, and capitalizing on the recovery of valuation multiples and earnings growth [32][34] - Specific recommendations include companies like Sanofi Pharmaceutical, Deqi Pharmaceutical, and Baiji Shenzhou, which have rich catalysts and are still undervalued [35] - **AI in Healthcare**: - The application of AI in healthcare is highlighted as a new theme for industry innovation, with significant market expansion potential [33] - **Future Outlook**: - The pharmaceutical industry is expected to maintain a stable upward trend in 2026, with a focus on fundamental performance and valuation [30] - The introduction of the commercial insurance innovative drug directory and ongoing policy reforms are anticipated to further enhance market sentiment and fundamental expectations [37]

Market Overview - On December 12, the Central Economic Work Conference emphasized the need for internal strengthening to address external challenges and to continue implementing a moderately loose monetary policy[1] - The Hang Seng Index rose by 446 points (1.8%) to close at 25,976 points, with a peak increase of 475 points during the day[1] - The Hang Seng Technology Index increased by 103 points (1.9%) to close at 5,638 points, with total market turnover expanding to HKD 242.7 billion[1] - Southbound capital experienced a net outflow of HKD 5.29 billion[1] Sector Performance - Gold prices increased, with Zijin Mining (2899 HK) rising by 3.6%, Shandong Gold (1787 HK) and Zhaojin Mining (1818 HK) both up by 3.4%[1] - Consumer stocks performed well, with Mengniu Dairy (2319 HK) up 2.7%, Nongfu Spring (9633 HK) up 2.2%, and Haidilao (6862 HK) up 2.9%[1] - Technology stocks also saw gains, with Alibaba (9988 HK) and Tencent (700 HK) rising by 2.3% and 2.4%, respectively[1] U.S. Market Dynamics - Despite interest rate cuts, U.S. tech stocks continued to decline, with the Nasdaq Composite falling by 245 points (0.5%) to close at 48,458 points[2] - The S&P 500 index dropped by 73 points, closing at 6,827 points, while long-term bond yields rose to 4.189%[2] Macroeconomic Indicators - As of the end of November, China's broad money supply (M2) stood at CNY 336.99 trillion, growing by 8% year-on-year, slightly below the market expectation of 8.2%[3] - Narrow money supply (M1) reached CNY 112.89 trillion, with a year-on-year growth of 4.9%, also below the expected 5.7%[3] - The loan balance grew by 6.4% year-on-year, down from the previous 6.5%[3] Industry Insights - In the automotive sector, stocks related to smart driving performed well, with Xiaoma Zhixing (2026 HK) up 4.9% and Horizon Robotics (9660 HK) up 3.8%[4] - The energy/utilities sector saw traditional power equipment stocks rise, with Dongfang Electric (1072 HK) increasing by 16.8% over the week[4] - The pharmaceutical sector remained stable, with WuXi AppTec (2359 HK) and WuXi Biologics (2269 HK) showing solid performance despite potential regulatory challenges[5]

Core Insights - The Hong Kong Technology ETF Tianhong (159128) has seen a significant increase in trading volume and net inflow, indicating strong investor interest in the technology sector [1][2] - The Hang Seng Technology ETF Tianhong (520920) also reported record highs in both scale and shares, reflecting robust performance in the technology market [1][2] Fund Performance - As of December 12, 2023, the Hong Kong Technology ETF Tianhong (159128) reached a scale of 1.312 billion yuan, marking a new high since its inception, with a weekly share increase of 22 million [1] - The Hang Seng Technology ETF Tianhong (520920) achieved a scale of 9.322 billion yuan and a total of 10.619 billion shares, both setting new records [1] Capital Inflows - The Hong Kong Technology ETF Tianhong (159128) has experienced continuous net inflows over the past 21 days, totaling 760 million yuan [1] - The Hang Seng Technology ETF Tianhong (520920) has seen net inflows for 32 consecutive days, with a peak single-day inflow of 191 million yuan, accumulating a total of 5.75 billion yuan [2] Market Trends - The Hong Kong stock market has witnessed a surge in share buybacks, with over 700 million shares repurchased in November 2023 alone, compared to lower monthly figures in previous months [2] - Leading technology companies like Tencent and Xiaomi are at the forefront of this buyback trend, indicating a strong commitment to stabilizing market confidence [2] Strategic Developments - The recent Central Economic Work Conference emphasized the importance of deepening and expanding "Artificial Intelligence+" initiatives, aligning with current technological advancements and governance needs [4] - The implementation of a stock buyback mechanism reform by the Hong Kong Stock Exchange in 2024 is expected to enhance corporate buyback activities, allowing companies to retain shares for reuse [3]

大消费高开高走收涨1.76%，其中同程旅行上涨2.05%，阿里健康上涨1.71%，康方生物上涨1.05%，百 济神州、理想汽车、京东健康、吉利汽车等股均小幅收涨。 恒生银行全天维持在中轴上方窄幅盘整，截至收盘上涨1.06%。其中招商银行上涨0.78%，浙商银行上 涨1.65%，重庆农村商业银行、大新金融携手上涨0.33%，民生银行、光大银行、中国银行等股逆势小 跌。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 港股迎来反转，高开高走后收涨1.75%。互联网涨幅居前，大消费、科技、银行等紧随其后，恒生医疗 相对偏弱。 恒生互联网高开高走后全天震荡上行，截至收盘大涨1.9%。其中商汤大涨4.74%，网易上涨4.2%，地平 线机器人上涨3.8%，阿里巴巴、腾讯控股等股涨幅均在2%上方。 ...

Investment Rating - The industry rating is "Outperform the Market" [7][76] Core Insights - The report emphasizes the importance of external demand-driven CXO investment opportunities due to the recent interest rate cuts by the Federal Reserve and the elimination of policy uncertainties related to the new Biosecurity Act [4][29] - The report highlights a mixed performance in the pharmaceutical sector, with a notable focus on innovative drugs and medical devices as key investment areas for the upcoming year [5][34] Summary by Sections Market Review - The CITIC Pharmaceutical Index fell by 1.1% during the week of December 8-12, 2025, underperforming the CSI 300 Index by 1.0 percentage points, ranking 15th among CITIC's primary industry classifications [3][34] - Year-to-date, the CITIC Pharmaceutical Biotech Index has risen by 15.6%, still underperforming the CSI 300 Index by 0.8 percentage points, ranking 16th [3][34] - Top-performing stocks for the week included Zhaoyan New Drug (+23.4%), Hotgen Biotech (+16.8%), and Haichuang Pharmaceutical (+13.9%) [3][53] Investment Opportunities - The Federal Reserve's recent interest rate cut is expected to improve overseas biotech investment and financing conditions, which will benefit CDMO (Contract Development and Manufacturing Organization) orders [4][21] - The new Biosecurity Act, which has passed the House and is awaiting Senate approval, is expected to have a limited impact on external demand for CXO companies, alleviating valuation pressures in the sector [4][28] Sector Performance - The pharmaceutical sector's overall valuation as of December 12, 2025, is 28.79, reflecting a slight decrease of 0.17, with a relative valuation premium of 12.02% compared to the broader market [44] - The total trading volume for the pharmaceutical sector during the week was 423.43 billion, accounting for 4.3% of the total A-share trading volume, with a 3.9% increase from the previous week [50][53]

Investment Rating - The industry rating is "Outperform the Market" [7] Core Insights - The report emphasizes the positive changes in the Biodefense Act and highlights the investment opportunities in external demand-oriented CXO companies due to the expected improvement in overseas financing and the easing of policy uncertainties [4][26] - The report notes that the recent Federal Reserve interest rate cut is expected to enhance overseas investment in the biotech sector, which will benefit CDMO companies through increased overseas orders [4][21] - The new Biodefense Act is less stringent than previous versions, which is expected to have a limited impact on external demand-oriented CXO companies, potentially lifting valuation pressures on the sector [4][26] Summary by Sections Market Review - During the week of December 8-12, 2025, the CITIC Pharmaceutical Index fell by 1.1%, underperforming the CSI 300 Index by 1.0 percentage points, ranking 15th among CITIC's primary industry classifications [3][32] - Year-to-date, the CITIC Pharmaceutical and Biotech Index has risen by 15.6%, underperforming the CSI 300 Index by 0.8 percentage points, ranking 16th among CITIC's industry classifications [3][32] - The top five performing stocks for the week were: Zhaoyan New Drug (+23.4%), Rejing Biotech (+16.8%), Haichuang Pharmaceutical (+13.9%), Wanze Co. (+13.4%), and Zhongyao Holdings (+13%) [3][49] Investment Opportunities - The report suggests focusing on innovative drugs, particularly those with revenue and commercialization capabilities, as well as potential big BD targets based on technological and industrial trends [5] - It also highlights opportunities in medical devices, especially in areas like endoscopy and robotics, and emphasizes the importance of innovative consumables supported by national policies [5] - The report indicates a shift towards domestic demand-driven companies as the central economic work conference emphasizes building a strong domestic market [5] Recommendations - The report recommends a focus on the following companies: Kangfang Biotech, WuXi AppTec, Kanglong Huacheng, Baiaosaitu, Bairen Medical, and Kangzhong Medical for December [5][12]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The 2025 National Medical Insurance Negotiation results were announced, with 114 new drugs added to the medical insurance directory, achieving an overall success rate of 88%, the highest in nearly seven years, with a maximum price reduction of 94 [4][19] - The newly added drugs include monoclonal antibodies, bispecific antibodies, ADCs, siRNA, and small molecules, indicating a strong focus on innovative therapies [19][32] - The commercial insurance directory has added 19 innovative drugs, which, while not reimbursed by medical insurance, receive support for innovative drug applications, enhancing patient access and benefiting the innovative drug industry [5][24] Summary by Sections 1. National Medical Insurance Negotiation Results - The 2025 medical insurance directory added 114 new drugs, with a success rate of 88% and a maximum price reduction of 94% [4][13] - The total number of drugs in the national medical insurance directory reached 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [16][17] - The directory reflects a significant increase in the inclusion of innovative drugs, with 50 of the new additions classified as category 1 innovative drugs [19][21] 2. Commercial Insurance Directory - The commercial insurance directory added 19 innovative drugs, highlighting their clinical value and innovation [24][28] - The directory includes treatments for diseases such as Alzheimer's, rare diseases in children, and other critical conditions, showcasing a focus on addressing unmet medical needs [24][28] - The support for innovative drugs in the commercial insurance directory aims to fill gaps in patient coverage and enhance the overall healthcare system [25][28] 3. Market Performance - In the second week of December, the pharmaceutical and biotechnology sector declined by 1.04%, underperforming the CSI 300 index by 0.96 percentage points [6][34] - The medical research outsourcing sector showed the highest increase, up by 3.69%, while offline pharmacy and medical circulation sectors experienced the largest declines [6][36] 4. Recommended Companies - The report continues to favor innovative drugs and their supply chain, recommending companies such as Sanofi, Innovent Biologics, and others for investment [7][32]